Vaxess Technologies has received the final tranche of its $8.2m series A round led by MIT-affiliated incubator and venture capital fund The Engine.
Vaxess Technologies, a US-based drug delivery patch developer based on research at Massachusetts Institute of Technology (MIT) and Tufts University, has closed an $8.2m series A round led by The Engine. Bioinnovation Capital also backed the round, which was raised over multiple tranches, though further details were not revealed. The Engine is an incubator and…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
